# *In vitro* global surveillance of eravacycline and comparators against *Staphylococcus* spp. and *Enterococcus* spp. over a three-year period (2013-15)

Matteo Bassetti, MD, PhD1, Ralph Corey, MD2, Yohei Doi, MD, PhD3, Ian Morrissey, PhD4, Trudy Grossman, PhD5, Melanie Olesky, PhD6, and Joyce Sutcliffe, PhD5

¹San Martino Hospital, Genova, Italy, ²Duke University Medical Center, Durham, NC, ³Division of Infectious Diseases, University of Pittsburgh, PA, ⁴IHMA Europe Sàrl, Epalinges, Switzerland, ⁵Consultant to Tetraphase Pharmaceuticals, Watertown, MA, ⁴Tetraphase Pharmaceuticals, Watertown, MA, of the same of



ontact:

Tetraphase Pharmaceuticals Medical Information (TPMI) medinfo@tphase.com 617-715-3600

### **Abstract**

Background: Eravacycline (ERV) is a novel, fully-synthetic fluorocycline antibiotic of the tetracycline class being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. As methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) have been designated as serious public threats by the CDC, the purpose of this study was to evaluate the activity of ERV and comparators against global isolates of Staphylococcus spp. and Enterococcus spp. collected from 2013-15.

Materials/methods: Clinical isolates were collected from various body sites in patients in hospitals worldwide from 2013-15. MIC results for ERV and comparators were determined by CLSI broth microdilution.

**Results:** ERV and comparator MIC results are shown in the table below.  $MIC_{90}$  values for the organisms did not vary more than one dilution over the 3-year time range.

Organism		ERV			TGC			VAN				
	N	MIC <sub>50/90</sub>	MIC Range	N	MIC <sub>50/90</sub>	MIC Range	N	MIC <sub>50/90</sub>	MIC Range			
Enterococcus faecalis	919	0.06/0.06	0.008-0.5	919	0.12/0.25	≤ 0.015-8	915	1/2	0.12->32			
VR E. faecalis	35	0.06/0.12	0.03/0.25	35	0.12/0.25	0.06-0.5	35	>32/>32	>16->32			
Enterococcus faecium	696	0.03/0.06	0.008-1	696	0.12/0.12	0.03-8	694	1/>32	≤ 0.12->32			
VR E. faecium	310	0.06/0.06	0.008-1	310	0.12/0.25	0.03-4	310	>32/>32	>16->32			
Staphylococcus aureus	1512	0.06/0.12	≤ 0.008-1	1512	0.12/0.25	0.03-1	532	1/1	≤ 0.25-2			
MRSA	756	0.06/0.12	0.015-1	756	0.12/0.25	0.03-1	263	1/1	<=0.25-2			
Staphylococcus epidermidis	483	0.12/0.5	≤ 0.008-1	483	0.25/0.5	≤ 0.015-1	206	2/2	0.5-2			
Staphylococcus haemolyticus	305	0.12/0.5	0.015-2	305	0.25/0.5	0.03-1	148	2/2	0.5-4			

MIC<sub>200707</sub> minimum inhibitory concentration required to inhibit growth of 50/90% of isolates (mg/L); VR, vancomycin-resistant; TGC, tigecycline; VAN, vancomycin

Conclusion: Eravacycline demonstrated consistent and potent in vitro activity against a global collection of Staphylococcus spp. and Enterococcus spp., including resistant strains, over a recent 3-year time period (2013-2015). The in vitro potency for ERV against these organisms was up to 4-fold greater than TGC and a minimum of 8-fold greater than VAN.

## Introduction

The Gram-positive organisms Staphylococcus aureus, Enterococcus spp. and coagulase-negative staphylococci are important pathogens in the hospital setting, accounting for 41% of all pathogens causing healthcare-associated infections.¹ Antibiotic resistance has increased in these organisms, and methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) have been designated as serious public threats by the CDC.² Together, MRSA and VRE are leading causes of healthcare-associated infections in the US, resulting in ~12,000 deaths per year.²³

Eravacycline (ERV) is a novel, fully-synthetic fluorocycline antibiotic of the tetracycline class being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. ERV is in phase 3 clinical development for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), including pyelonephritis.

The purpose of this study was to evaluate the activity of ERV and comparators against global isolates of *Staphylococcus* spp. and *Enterococcus* spp. collected over a three-year surveillance period (from 2013-2015).

#### Methods

- A total of 4,015 clinical isolates, collected from various body sites from 2013-2015 from 205 hospitals, were tested. Breakdowns by country and site of infection are given in Figures 1 and 2, respectively.
- Minimal inhibitory concentration (MIC) endpoints were determined by broth microdilution according to CLSI guidelines.<sup>4</sup>
- Quality control testing was performed each day of testing as specified by the CLSI using Enterococcus faecalis ATCC 29212 and Staphylococcus aureus ATCC 29213.
- Antibiotic susceptibility was determined using CLSI 2015 breakpoints<sup>5</sup>, with the exception of tigecycline where FDA breakpoints were used.<sup>6</sup>

Figure 1. Isolate counts (n, %) by country of origin for the 4,015 isolates collected from 2013-2015





Figure 2. Isolate counts by source of infection for the 4,015 isolates collected from 2013-2015



#### Results

- Clinical isolates were from diverse geographic locations, with 47% from countries within North America (specifically, the United States), 47% from within Europe, 5% from within Asia, and 1% from within the South Pacific (Fig. 1).
- Most isolates were collected from GU, respiratory, bodily fluid and skin/ wound infection sources followed by GI and blood (Fig. 2).
- Tables 1 and 2 show MIC values for staphylococci and enterococci, respectively.
- ERV MIC<sub>90</sub> values for the organisms did not vary more than one dilution over the 3-year time range.
- Cumulative MIC distribution patterns for MRSA and VRE organisms were similar for each of the three years, with some differences observed in the 0.015-0.06 mg/L MIC range.
- The in vitro activity (as measured by MIC<sub>90</sub> values) for ERV against S. aureus, including MRSA, was up to 4-fold more potent than tigecycline and primarily 4-fold more potent than minocycline. ERV showed up to 4-fold greater activity than tigecycline, >64-fold greater activity than minocycline, and a minimum of 8-fold greater activity than vancomycin against tested enterococci, including VRE.

Figure 3. MIC distribution (Cumulative %) for ERV against 756 MRSA and 345 VRE (including VR *E. faecium* and VR *E. faecalis*)




Table 1. Antimicrobial activity of ERV and comparator agents against Staphylococcus spp., including resistant isolates, from 2013-2015

Azithromycin Ceftriaxone	2	16	≤0.12	> 16			-	2	16	0.25	> 16		-		>1	>1	0.25	>1	-	-	
A.A.	>8	>8	0.25	> 8	43.5%	0.3%	56.1%	>8	> 8	0.5	>8	43.1%	0%	56.9%	1	>4	≤ 0.25	>4	52.6%	0.2%	47.25
	16	> 64	1	> 64			-	8	> 64	2	> 64										
Daptomycin	0.5	1	0.25	4	99.5%			0.5	1	0.25	4	99.1%			0.25	0.5	0.12	2	99.8%		
Daptorijen	0.3	0.12	0.23	-	33.374		-	0.5	0.12	0.23	_	22.170			0.23	0.5	< 0.02	_	27.2.4	-	_
travacychne	0.06		0.015	- 1		-	-	0.00		0.03	- 1				0.06	0.06			-	-	-
Levofloxacin	0.5	>8	≤ 0.03	> 8	65.3%	0%	34.7%	0.5	> 8	0.12	>8	66.1%	0%	33.9%	0.25	>4	0.06	>4	57.9%	0.8%	41.4
Linezolid	2	2	≤0.5	2	100%		0%	2	2	1	2	100%		0%	1	2	≤ 0.5	2	100%		0%
Minocycline	0.12	0.25	≤ 0.03	>8	96.2%	1.7%	2.1%	0.12	0.25	≤ 0.03	8	99.1%	0.9%	0%	0.12	0.25	≤ 0.05	>8	96.2%	1.9%	1.99
Penicillin	>8	>8	< 0.12	18	12.6%		87.4%	>8	18	< 0.12	>8	7.9%		92.7%	> 2	5.2	< 0.12	>2	14 1%		85.9
Tetracycline	0.5	16	<0.06	> 32	89.2%	0.7%	10.1%	0.5		0.12	> 32	89.9%	0.9%	9.2%	0.25	16	≤ 0.06	>16	88 94	0.4%	10.7
		0.25	0.03		99.1%	U.7%	0.9%					99.1%	U.9%	0.9%						0.4%	
Tigecycline	0.12	0.25	0.03	1	99.1%	-	0.9%	0.12	0.25	0.06	1	99.1%	-	0.9%	0.12	0.25	0.06	1	99.1%	-	0.99
	MRSA (4							MRSA							MRSA						
Amoxicillin Clavulanate	8	16	1	> 16	-	-	-	8	16	1	> 16	-	-		> 1	> 1	1	>1	-	-	-
Azithromycin	>8	>8	0.5	>8	19%	0%	81%	>8	>8	0.5	>8	13.3%	0%	86.7%	>4	>4	≤ 0.25	>4	24.3%	0.4%	75.3
Ceftriaxone	> 64	> 64	4	> 64				> 64	> 64	4	> 64		_								
Daptomycin	1	1	0.25	4	99.3%			0.5	1	0.25	4	97.8%			0.25	0.5	0.12	2	99.6%		
		-	0.13	-	33.3.4	-	_	0.7		0.03	- 1	37.074	-	-	0.13	0.12	0.015	-	23.03	_	_
Eravacycline	0.06	10,172	0.015	- 1		-	-	0.00	0.25						0.00					-	
Levofloxacin	8	> 8	0.12	> 8	43.8%	0%	56.3%	8	>8	0.25	>8	33.3%	0%	66.7%	>4	>4	0.06	>4	22.4%	1.5%	76.1
Linezolid	2	2	1	2	100%	-	0%	2	2	1	2	100%	-	0%	1	2	≤ 0.5	2	100%	-	0%
Minocycline	0.12	0.25	≤ 0.03	>8	94.6%	2.7%	2.7%	0.12	0.5	≤ 0.03	8	97.8%	2.2%	0%	0.12	4	≤ 0.06	>8	92.4%	3.8%	3.85
Penicillin	>8	>8	0.5	>8	0%		100%	>8	>8	0.25	>8	0%	_	100%	> 2	> 2	≤ 0.12	>2	0.8%		99.2
Tetracycline	0.5	32	0.12	> 32	85.9%	0.2%	13.8%	0.5	92	0.12	> 32	88 9%	0%	11.1%	0.25	> 16	≤ 0.06	>16	83.7%	0.4%	16.0
	0.12	0.25	0.03	1	98.2%		1.8%	0.12	0.5	0.06	1	97.8%	0,4	2.2%	0.12	0.25	0.06	1	98.1%	2.4.4	
Tigecycline				1	96.2%		1.6%				1	37.8%		2.2%				- 1	345.1%		1.99
	S. epide	rmidis (2						S. epid	lermidis (						S. epide	nneoidis (:					
Amoxicillin Clavulanate	2	16	≤ 0.12	> 16			-	2	8	0.5	16				>1	> 1	≤ 0.06	>1			
Azithromycin	> 8	>8	≤ 0.12	> 8	34.1%	0.4%	65.5%	>8	>8	0.25	>8	28%	0%	72%	>4	>4	≤ 0.25	>4	39.8%	0%	60.2
Ceftriaxone	16	> 64	≤0.5	> 64			-	16	64	≤0.5	> 64										
Daptomycin	1	1	0.25	4	98.0%			0.5	1	0.5	1	100%	-		0.5	0.5	≤ 0.06	1	100%		_
Francisco	0.25	0.5	0.015	-	-			0.25	0.5	0.06	0.5				0.12	0.5	<0.008	1	-		
Levofloxacin	4	>8	0.12	>8	46.8%	0.8%	52.4%	8	>8	0.25	>8	36%	0%	64%	2	>4	0.12	>4	42.7%	10.7%	46.6
						U.856							Une							10.7%	
Linezolid	1	2	≤0.5	> 8	98.8%		1.2%	2	2	1	2	100%		0%	≤0.5	1	≤ 0.5	>4	99%		196
Minocycline	0.25	0.5	≤ 0.03	1	100%	0%	0%	0.25	0.5	0.06	>8	96%	0%	4%	0.25	0.5	≤ 0.06	4	100%	0%	0%
Penicillin	4	>8	≤ 0.12	>8	11.5%		88.5%	4	>8	≤ 0.12	>8	8%		92%	> 2	> 2	≤ 0.12	>2	9.7%		90.3
Tetracycline	2	> 32	0.12	> 32	82.1%	1.6%	16.3%	2	8	0.25	> 32	88%	456	8%	1	16	≤ 0.05	>16	87.4%	2.4%	10.2
Tigecycline	0.25	0.5	0.03	1	92.9%		7.1%	0.25	0.5	0.06	1	96%	_	4.0%	0.12	0.25	≤ 0.015	0.5	100%	_	0%
- Grejann		-		-							-							-			
	MRSE (1							MRSE													
Amoxicillin Clavulanate	2	16	≤ 0.12	> 16	-	-	-	2	8	2	8		-								
Azithromycin	> 8	>8	≤ 0.12	>8	24.7%	0.6%	74.7%	>8	>8	0.5	> 8	20%	0%	80%							
Ceftriaxone	16	> 64	≤ 0.5	> 64	-	-	-	32	64	8	64										
Daptomycin	0.5	1	0.25	4	97.6%	-	_	0.5	1	0.5	1	100%	_								
Eravacycline	0.25	0.5	0.015	- 1				0.25	0.5	0.06	0.5										
Levofloxacin		>8	0.25	>8	31.9%	1.2%	66.9%	8	>8	0.25	>8	20%	0%	82%	1						
Linezolid	1	2	£0.5	>8	98.2%	2.2.0	1.8%	2	2	1	2	100%	0.90	0%							
						-							-								
Minocycline	0.25	0.5	≤ 0.03	1	100%	0%	0%	0.25	0.5	0.06	>8	93.3%	0%	6.7%							
Penicillin	8	> 8	≤ 0.12	>8	1.2%	-	98.8%	4	>8	1	>8	0%	-	100%							
Tetracycline	2	> 32	0.12	> 32	80.7%	2.4%	16.9%	2	32	0.25	> 32	80%	6.7%	13.3%							
Tigecycline	0.25	0.5	0.03	1	94.0%	-	6.0%	0.5	0.5	0.12	1	93.3%	_	6.7%							
	S horm	nobeticus	(123)					S. hoer	molyticus	(%4)					S hoon	nolyticus	(148)				
Amoxicillin Clavulanate	16.	> 16	<0.12	× 16				s. noes	> 16	1	> 16				> 1	> 1	0.12	>1			
Amoxicilin Clavulanate Azithromycin		> 16	≤ 0.12 ≤ 0.12	>16	20.3%	0%				- 1											
	>8																				
					20.3%	0%	79.7%	>8	> 8	0.25	>8	23.5%	0%	76.5%	>4	>4	≤ 0.25	>4	18.2%	0%	81.8
Ceftriaxone	> 64	> 64	1	> 64			79.7%	> 64	> 64	4	>8 >64		0%	76.5%	>4			>4		0%	81.8
Ceftriaxone	> 64 0.5				20.3%	-	79.7%				>8	23.5%	0% 	76.5%		> 4 0.5	≤ 0.25 0.12		18.2%	0%	81.8
Ceftriaxone		> 64	1	> 64		-	79.7%	> 64	> 64	4	>8 >64		0% - -	76.5%	>4			>4		0%	81.8
Ceftriaxone Daptomycin Envasychno	0.5	> 64 0.5	1 0.12 0.015	> 64 2 1	99.2%	-	-	> 64 0.25 0.12	> 64 0.5 0.25	4 0.12 0.03	>8 >64 1 0.5	100%	-	-	0.5	0.5	0.12	>4 1 2	100%	-	-
Ceftriaxone Daptomycin Levofloxacin	0.5	> 64 0.5 0.5 > 8	0.12 0.015 0.06	>64 2 1 >8	99.2%		76.4%	> 64 0.25 0.12 8	> 64 0.5 0.25 > 8	0.12 0.03 0.12	>8 >64 1 0.5 >8	100%	0%  	67.7%	>4 0.5 0.12 >4	0.5	0.12	1 2 34	100%	- 0% - 0.7%	78.4
Ceftriaxone Daptomycin  Forescycles Levofloxacin Linezolid	0.5 0.25 8 2	> 64 0.5 0.5 > 8 2	1 0.12 0.015 0.06 ≤ 0.5	>64 2 1 >8 >8	23.6% 99.2%	0%	- - 76.4% 0.8%	> 64 0.25 0.12 8 1	> 64 0.5 0.15 > 8 2	4 0.12 0.03 0.12 1	>8 >64 1 0.5 >8 2	 100% 32.4% 100%	0%	67.7%	>4 0.5 0.12 >4 1	0.5 0.5 > 4 1	0.12 0.015 0.06 ≤ 0.5	>4 1 2 >4 2	100% 	0.7%	78.4
Ceftriaxone Daptomycin  Levergorie Levefloxacin Linezolid Minocycline	0.5 0.25 8 2 0.25	> 64 0.5 0.5 > 8 2 0.5	1 0.12 0.015 0.06 ≤ 0.5 ≤ 0.03	> 64 2 1 > 8 > 8	23.6% 29.2% 29.2% 29.2%	-	76.4% 0.8% 0%	> 64 0.25 0.12 8 1 0.25	> 64 0.5 0.05 > 8 2 0.25	4 0.12 0.03 0.12 1 0.06	>8 >64 1 0.5 >8 2 2	100% 32.4% 100% 100%	-	  67.7% 0%	>4 0.5 0.12 >4 1 0.25	0.5 0.5 > 4 1 0.25	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06	>4 1 2 >4 2 1	100% 21.0% 100% 100%	-	78.4 0%
Ceftriaxone Daptomycin  Ferracycine Levofloxacin Linezolid Minocycline Penicillin	0.5 0.25 8 2 0.25 >8	> 64 0.5 0.5 > 8 2 0.5 > 8	1 0.12 0.015 0.06 ≤ 0.5 ≤ 0.03 ≤ 0.12	>64 2 1 >8 >8 >8 8 >8	99.2% 23.6% 99.2% 99.2% 99.2%	0%	76.4% 0.8% 0% 90.2%	> 64 0.25 0.12 8 1 0.25 > 8	> 64 0.5 0.25 > 8 2 0.25 > 8	4 0.12 0.03 0.12 1 0.06 \$ 0.12	>8 >64 1 0.5 >8 2 2 2 >8	32.4% 100% 100% 100% 20.6%	- - 0% - 0% -	  67.7% 0% 0% 79.4%	>4 0.5 0.12 >4 1 0.25 >2	0.5 0.5 > 4 1 0.25 > 2	0.12 0.015 0.06 \$ 0.5 \$ 0.06 \$ 0.12	>4 1 2 >4 2 1 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8
Ceftriaxone Daptomycin Eravacycline Levofloxacin Linezolid Minocycline Penicillin	0.5 0.25 8 2 0.25	> 64 0.5 0.5 > 8 2 0.5	1 0.12 0.015 0.06 ≤ 0.5 ≤ 0.03	> 64 2 1 > 8 > 8	23.6% 29.2% 29.2% 29.2%	0%	76.4% 0.8% 0%	> 64 0.25 0.12 8 1 0.25	> 64 0.5 0.05 > 8 2 0.25	4 0.12 0.03 0.12 1 0.06	>8 >64 1 0.5 >8 2 2	100% 32.4% 100% 100%	0%	  67.7% 0%	>4 0.5 0.12 >4 1 0.25	0.5 0.5 > 4 1 0.25	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06	>4 1 2 >4 2 1	100% 21.0% 100% 100%	0.7%	78.4 0% 0% 85.8
Ceftriaxone Daptomycin  Erwacycline Levofloxacin Linezolid Minocycline Penicillin Tetracycline	0.5 0.25 8 2 0.25 >8	> 64 0.5 0.5 > 8 2 0.5 > 8	1 0.12 0.015 0.06 ≤ 0.5 ≤ 0.03 ≤ 0.12	>64 2 1 >8 >8 >8 8 >8	99.2% 23.6% 99.2% 99.2% 99.2%	0%	76.4% 0.8% 0% 90.2%	> 64 0.25 0.12 8 1 0.25 > 8	> 64 0.5 0.25 > 8 2 0.25 > 8	4 0.12 0.03 0.12 1 0.06 \$ 0.12	>8 >64 1 0.5 >8 2 2 2 >8	32.4% 100% 100% 100% 20.6%	- - 0% - 0% -	  67.7% 0% 0% 79.4%	>4 0.5 0.12 >4 1 0.25 >2	0.5 0.5 > 4 1 0.25 > 2	0.12 0.015 0.06 \$ 0.5 \$ 0.06 \$ 0.12	>4 1 2 >4 2 1 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Ceftriaxone Daptomycin  fenescycline Levofloxacin Linezolid Minocycline Penicillin Tetracycline	0.5 0.25 8 2 0.25 >8 1 0.25	> 64 0.5 0.5 > 8 2 0.5 > 8 > 32	1 0.12 0.015 0.06 ≤0.5 ≤0.03 ≤0.12 ≤0.06 0.03	>64 2 1 >8 >8 >8 >8 >8	 99.2%  23.6% 99.2% 99.2% 9.8% 76.4%	0%	76.4% 0.8% 0% 90.2% 23.6%	> 64 0.25 0.12 8 1 0.25 > 8 1	> 64 0.5 0.25 > 8 2 0.25 > 8 32	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12	>8 >64 1 0.5 >8 2 2 2 >8 >32	100% 32.4% 100% 100% 20.6% 88.2%	- - 0% - 0% -	  67.7% 0% 0% 79.4% 11.8%	>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Ceftrizzone Daptomycin Frezeycise Levofloracin Linezold Minocycline Peniolilin Tetracycline Tigacycline	0.5 0.25 8 2 0.25 >8 1 0.25 \$.hemo	> 64 0.5 0.5 > 8 2 0.5 > 8 > 32 0.5	1 0.12 0.015 0.06 ≤0.5 ≤0.03 ≤0.12 ≤0.06 0.03	> 64 2 1 > 8 > 8 8 > 8 > 32 1	 99.2%  23.6% 99.2% 99.2% 9.8% 76.4%	0%	76.4% 0.8% 0% 90.2% 23.6%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 S. hem	> 64 0.5 0.65 > 8 2 0.25 > 8 32 0.5	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1)	>8 >64 1 0.5 >8 2 2 2 >8 >32 1	100% 32.4% 100% 100% 20.6% 88.2%	- - 0% - 0% -	  67.7% 0% 0% 79.4% 11.8%	>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Ceftriaxone Daptomycin foresty clere Levofloxacin Lineacid Minocycline Periolilin Tetracycline Tigacycline Amosicilin Clavulanate	0.5 0.25 8 2 0.25 > 8 1 0.25 \$.hemo	> 64 0.5 0.5 > 8 2 0.5 > 8 > 32 0.5 olyticus, 1 > 16	1 0.12 0.015 0.06 ≤ 0.5 ≤ 0.03 ≤ 0.12 ≤ 0.06 0.03 MR (SB)	> 64 2 1 > 8 > 8 > 8 > 32 1 > 16	23.6% 29.2% 29.2% 99.2% 99.2% 9.8% 76.4% 92.7%	0%  0.8%  0% 	76.4% 0.8% 0% 90.2% 23.6% 7.3%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 \$ .hem > 16	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 relyticus,	4 0.12 0.12 1 0.06 ≤ 0.12 0.25 0.12 MR (1) > 16	>8 >64 1 0.5 >8 2 2 2 >8 >32 1	 100% 32.4% 100% 100% 20.6% 88.2% 97.1%	  0%  0% 	67.7% 67.7% 0% 0% 79.4% 11.8% 2.9%	>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 85.8 18.2 0.79
Ceftriasone Daptomycin  Errecycles Levellosacin Lineacid Minocycline Periodiin Tetracycline Tigecycline Amoxicolin Clavulanate Abthromycin	0.5 8 2 0.25 >8 1 0.25 \$.hemo >16 >8	> 64 0.5 > 8 2 0.5 > 8 > 32 0.5 olyticus, 1 > 16 > 8	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (SB) 0.5 \$0.12	> 64 2 3 > 8 > 8 > 8 > 32 1 > 16 > 8	 99.2%  23.6% 99.2% 99.2% 9.8% 76.4%	0%	76.4% 0.8% 0% 90.2% 23.6%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 \$ hem > 16 > 8	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 solyticus, > 16 > 8	4 0.12 0.03 0.12 1 0.06 ≤0.12 0.25 0.12 MR (1) >16 >8	>8 > 64 1 0.5 >8 2 2 >8 > 32 1 > 16 >8	100% 32.4% 100% 100% 20.6% 88.2%	- - 0% - 0% -	  67.7% 0% 0% 79.4% 11.8%	>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Ceftriaxone Daptomycin Errestyclire Levofloxacin Linezold Minocycline Periolilin Tetracycline Tigecycline Amodollin Clavulanate Authromycin Ceftriaxone	0.5 8 2 0.25 >8 1 0.25 \$ hemo > 16 > 8 > 64	> 64 0.5 > 8 2 0.5 > 8 > 32 0.5 slyticus, 8 > 16 > 8 > 64	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (\$8) 0.5 \$0.12	> 64 2 3 3 8 8 8 > 8 > 32 1 > 16 > 8 > 64	99.2% 23.6% 99.2% 99.2% 99.2% 76.4% 92.7%	0%  0.8%  0% 	76.4% 0.8% 0% 90.2% 23.6% 7.3%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 \$ hem > 16 > 8 > 64	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 relyticus, > 16 > 8 > 64	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1) > 16 > 8 > 64	>8 > 64 1 0.5 >8 2 2 >8 > 32 1 >16 >8 >64	32.4% 100% 100% 100% 20.6% 88.2% 97.1%	  0%  0% 	67.7% 67.7% 0% 0% 79.4% 11.8% 2.9%	>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Ceftriasone Daptomycin  Errecycles Levellosacin Lineacid Minocycline Periodiin Tetracycline Tigecycline Amoxicolin Clavulanate Abthromycin	0.5 8 2 0.25 >8 1 0.25 \$.hemo >16 >8	> 64 0.5 > 8 2 0.5 > 8 > 32 0.5 olyticus, 1 > 16 > 8	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (SB) 0.5 \$0.12	> 64 2 3 > 8 > 8 > 8 > 32 1 > 16 > 8	23.6% 29.2% 29.2% 99.2% 99.2% 9.8% 76.4% 92.7%	0%  0.8%  0% 	76.4% 0.8% 0% 90.2% 23.6% 7.3%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 \$ hem > 16 > 8	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 solyticus, > 16 > 8	4 0.12 0.03 0.12 1 0.06 ≤0.12 0.25 0.12 MR (1) >16 >8	>8 > 64 1 0.5 >8 2 2 >8 > 32 1 > 16 >8	 100% 32.4% 100% 100% 20.6% 88.2% 97.1%	  0%  0% 	67.7% 67.7% 0% 0% 79.4% 11.8% 2.9%	>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Ceftriaxone Daptomycin Errestyclire Levofloxacin Linezold Minocycline Periolilin Tetracycline Tigecycline Amodollin Clavulanate Authromycin Ceftriaxone	0.5 8 2 0.25 >8 1 0.25 \$ hemo > 16 > 8 > 64	> 64 0.5 > 8 2 0.5 > 8 > 32 0.5 slyticus, 8 > 16 > 8 > 64	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (\$8) 0.5 \$0.12	> 64 2 3 3 8 8 8 > 8 > 32 1 > 16 > 8 > 64	99.2% 23.6% 99.2% 99.2% 99.2% 76.4% 92.7%	0%  0.8%  0% 	76.4% 0.8% 0% 90.2% 23.6% 7.3%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 \$ hem > 16 > 8 > 64	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 relyticus, > 16 > 8 > 64	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1) > 16 > 8 > 64	>8 > 64 1 0.5 >8 2 2 >8 > 32 1 >16 >8 >64	32.4% 100% 100% 100% 20.6% 88.2% 97.1%	  0%  0% 	67.7% 67.7% 0% 0% 79.4% 11.8% 2.9%	>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Celfriasone Daptomycin Francyciae Levelloxacin Lineaddi Lineaddi Tetracycine Tetracycine Tigacycline Tigacycline Anthromycin Celfriasone Daptomycin Daptomycin	0.5 8 2 0.25 >8 1 0.25 S. hemo >16 >8 >64 0.5	> 64 0.5 > 8 2 0.5 > 8 > 32 0.5 slyticus, 8 > 16 > 8 > 64	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (\$8) 0.5 \$0.12	> 64 2 3 3 8 8 8 > 8 > 32 1 > 16 > 8 > 64	99.2% 23.6% 99.2% 99.2% 99.2% 92.3% 76.4% 92.7%	0%  0.8%  0% 	76.4% 0.8% 0% 90.2% 23.6% 7.3%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 \$ hem > 16 > 8 > 64	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 relyticus, > 16 > 8 > 64	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1) > 16 > 8 > 64	>8 > 64 1 0.5 >8 2 2 >8 > 32 1 >16 >8 >64	32.4% 100% 100% 100% 20.6% 88.2% 97.1%	  0%  0% 	67.7% 67.7% 0% 0% 79.4% 11.8% 2.9%	>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Colfrisone Deploment  Francyclas Levellossin Lineckid Minocycline Penciclin Penciclin Penciclin Penciclin Penciclin Citarycline Tipscycline Antoxicilin Clavulanate Anthonycin Colfrisone Deplomycin Linecycline Linecycline	0.5 0.25 8 2 0.25 >8 1 0.25 > 8 1 0.25 \$ hemo > 16 > 8 > 64 0.5 0.112 > 8	> 64 0.5 > 8 2 0.5 > 8 > 32 0.5 > 16 > 8 > 64 0.5 > 8	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (58) 0.5 \$0.12 4 0.12 0.015 0.06	>64 2 1 >8 8 8 8 >8 >32 1 >16 >8 >64 1 1 >8	99.2% 23.6% 99.2% 99.2% 99.2% 9.8% 76.4% 92.7% 	0% 0% 0% 0%	76.4% 0.8% 0% 90.2% 23.6% 7.3%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 \$ hem > 16 > 8 > 64 0.5	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 solyticus, > 16 > 8 > 64 0.5	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1) > 16 > 8 > 64 0.5 0.05	>8 > 64 1 0.5 >8 2 2 >8 >32 1 >16 >8 >64 0.5 0.06 0.5	100% 32.4% 100% 100% 20.6% 88.2% 97.1% 	  0%  0%  0% 		>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Colfrisance Daptomyrin Evanogation Lineadid Minocycline Penidilis Tetracycline Tetracycline Antoxicilin Clavulanate Aithiromycin Ceftrisance Daptomyrin Evanogation Lineadid Lineadid Lineadid	0.5 0.25 8 2 0.25 >8 1 0.25 \$.hemo >16 >8 >64 0.5 0.11 >8 1	> 64 0.5 > 8 2 0.5 > 8 > 32 0.5 > 16 > 8 > 64 0.5 > 8	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (SB) 0.5 \$0.12 4 0.12 0.015 0.06 \$0.5	>64 2 1 >8 >8 >8 >8 >8 >932 1 >16 >64 1 1 >8 >8 >8 >8 >8 >8 >8 >932 1	99.2% 23.6% 99.2% 99.2% 99.8% 76.4% 92.7% 100% 20.7% 98.3%	0% 0%	76.4% 0.8% 0% 90.2% 23.6% 7.3% - 77.6% - - - 79.3% 1.7%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 \$ 5.hem > 16 0.5 0.5 0.5 0.5 0.5	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 solyticus, > 16 > 8 > 64 0.5 0.5 0.5	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1) > 16 > 8 > 64 0.5 0.05 0.5 2	>8 >64 1 0.5 >8 2 2 >8 >32 1 >16 >8 >64 0.5 0.06	100% 32.4% 100% 100% 20.6% 88.2% 97.1% 0% 100% 100%			>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Celtrisance Deptompein  Francycise Levellossein Levellossein Levellossein Minocycline Petacycline Tetacycline Tetacycline Tetacycline Tetacycline Celtrisance Outloomycin Francycline Levellossein Levellossein Levellossein	0.5 0.25 8 2 0.25 >8 1 0.25 \$ \$ 1 0.25 \$ \$.hemo >16 >8 >64 0.5 0.12 >8 1 0.25	> 64 0.5 > 8 2 0.5 > 8 32 0.5 > 8 > 32 0.5 > 8 > 364 0.5  > 8 2 0.5 > 8 2 0.5	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (58) 0.5 \$0.12 4 0.12 0.015 0.06 \$0.5 \$0.03	>64 2 1 >8 >8 >8 >8 >8 >32 1 >16 >16 >8 >64 1 1 >8 >8 0.5	99.2%	0% 0% 0% 0%	76.4% 0.8% 0% 90.2% 23.6% 7.3% - 77.6% 79.3% 1.7% 0%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 5. hem > 16 > 8 > 64 0.5 0.5 0.5 2 2	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 nolyticus, > 16 > 8 > 64 0.5 0.00 0.5 2 2	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1) > 16 > 8 > 64 0.5 0.15 0.5 2 2	>8 > 64 1 0.5 >8 2 2 >8 > 32 1 > 16 >8 > 64 0.5 0.06 0.5 2 2	100% 100% 100% 100% 20.6% 88.2% 97.1% 	  0%  0%  0% 		>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Celtrisane Daptomycin Exercycine Levellossin Levellossin Levellossin Levellossin Moncycline Periodili Tetracycline Tigacycline Tigacycline Celtrisane Daptomycin Exercycline Tigacycline Moncycline Lineadd Moncycline Lineadd Moncycline	0.5 0.25 8 2 0.25 >8 1 0.25 \$ 1 0.25 \$.hemo >16 >8 >64 0.5 0.12 >8 1 0.25 >8	> 64 0.5 > 8 2 0.5 > 8 > 32 0.5 > 0.5 > 8 > 32 0.5 > 8 > 32 0.5 > 8 > 16 > 8 > 8 > 16 > 16 > 16 > 16 > 16 > 16 > 16 > 16	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (S8) 0.5 \$0.12 4 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12	>64 2 1 >8			76.4% 0.8% 0% 90.2% 73.6% 77.6% 	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 5. hem > 16 > 8 > 64 0.5 0.5 0.5 2 2 2 0.5	> 64 0.5 0.05 > 8 2 0.25 > 8 32 0.5 > 16 > 8 > 64 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1) > 16	>8 >64 1 0.5 >8 2 2 >8 >32 1 >16 >65 >8 2 2 >8 >32 2 1 2 >64 0.5 >64 0.5 2 2 0.5	100% 32.4% 100% 100% 20.6% 88.2% 97.1% 			>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2
Celtrisance Deptompein  Francycise Levellossein Levellossein Levellossein Minocycline Petacycline Tetacycline Tetacycline Tetacycline Tetacycline Celtrisance Outloomycin Francycline Levellossein Levellossein Levellossein	0.5 0.25 8 2 0.25 >8 1 0.25 \$ \$ 1 0.25 \$ \$.hemo >16 >8 >64 0.5 0.12 >8 1 0.25	> 64 0.5 > 8 2 0.5 > 8 32 0.5 > 8 > 32 0.5 > 8 > 364 0.5  > 8 2 0.5 > 8 2 0.5	1 0.12 0.015 0.06 \$0.5 \$0.03 \$0.12 \$0.06 0.03 MR (58) 0.5 \$0.12 4 0.12 0.015 0.06 \$0.5 \$0.03	>64 2 1 >8 >8 >8 >8 >8 >32 1 >16 >16 >8 >64 1 1 >8 >8 0.5	99.2%	0% 0%	76.4% 0.8% 0% 90.2% 23.6% 7.3% - 77.6% 79.3% 1.7% 0%	> 64 0.25 0.12 8 1 0.25 > 8 1 0.25 5. hem > 16 > 8 > 64 0.5 0.5 0.5 2 2	> 64 0.5 0.25 > 8 2 0.25 > 8 32 0.5 nolyticus, > 16 > 8 > 64 0.5 0.00 0.5 2 2	4 0.12 0.03 0.12 1 0.06 \$0.12 0.25 0.12 MR (1) > 16 > 8 > 64 0.5 0.15 0.5 2 2	>8 > 64 1 0.5 >8 2 2 >8 > 32 1 > 16 >8 > 64 0.5 0.06 0.5 2 2	100% 100% 100% 100% 20.6% 88.2% 97.1% 			>4 0.5 0.12 >4 1 0.25 >2 1	0.5 0.5 > 4 1 0.25 > 2 > 16	0.12 0.015 0.06 ≤ 0.5 ≤ 0.06 ≤ 0.12 0.12	>4 1 2 >4 2 1 2 1 >4 2 1 >2 1 >2 1 >6 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2	100% 	- 0.7% - 0% -	78.4 0% 0% 85.8 18.2

Table 2. Antimicrobial activity of ERV and comparator agents against *Enterococcus* spp., including resistant strains, from 2013-2015

	2013 MIC (mg/L)						2014 MIC (mg/L)								2015 MIC (mg/L)							
			(mg/L) Ran		565	961	56R				nge	365	50	96R	MIC,		mg/L) Range		%5	50	*	
Antimicrobial Agent	MICso	MIC <sub>10</sub>	Min	Max				MICso	MIC <sub>60</sub>	Min	Max				MIK.	MIC <sub>10</sub>		Taox				
	£. foec	alis (433)						£. facc	rolis (68)						E. fac	celis (418)						
Amoxicillin Clavulanate	1	2	≤ 0.12	> 16				1	1	0.25	2				1	1	≤ 0.12	>1				
Azithromycin	>8	>8	≤ 0.12	> 8				>8	>8	0.5	> 8											
Ceftriaxone	>64	> 64	≤ 0.5	> 64				> 64	> 64	2	> 64											
Daptomycin	2	4	≤ 0.06	>4	99.3%			2	4	≤ 0.06	4	100%			1	2	0.06	8	99.8%			
	0.06							0.06							0.06							
Levofloxacin	2	>8	≤ 0.03	>8	67.9%	0.5%	31.6%	2	>8	0.5	>8	55.9%	1.5%	42.7%	1	>8	0.25	>8	70.6%	0.2%	29	
Lineaplid	2	2	≤ 0.5	4	29.3%	0.7%	0%	2	2	1	4	98.5%	1.5%	0%	1	1	0.25	4	99.8%	0.2%	c	
Minocycline	8	>8	≤ 0.03	>8	31.9%	18.2%	49.9%	8	>8	0.06	>8	27.9%	25%	47.1%	8	>8	≤ 0.03	>8	31.1%	39.5%	29	
Penicillin	2	4	≤ 0.12	>8	98.9%		1.2%	2	4	0.5	8	100%		0%	2	4	0.5	>8	96.7%		3.	
Tetracycline	> 32	> 32	0.12	> 32	26.6%	0.9%	72.5%	32	> 32	0.25	> 32	17.7%		82.4%	> 32	> 32	≤ 0.06	> 32	21.3%	0.2%	78	
Tigecycline	0.12	0.25	< 0.015	,	97.5%			0.12	0.25	£	0.25	100%			0.12	0.25	0.015		99%			
										0.015												
Vancomycin	1	2	0.12	> 32	92.5%	3%	4.4%	1	4	1	> 32	91.2%		8.8%	1	2	0.5	>16	97.4%	0.2%	2.4	
	E. foec	alis, VR (:	0.5						relix, VR (						E. faes	celis, VR (10)	0.5					
Amoxicilin Clavulanate	-	-		> 16				1	-	1	1				1	1	0.5	1				
Azithromycin	>8	>8	2	>8				> 8	>8	4	>8			-								
Ceftriaxone	>64	> 64	4	> 64				> 64	> 64	>64	> 64											
Daptomycin	2	2	1	4	100%	-		2	4	0.5	4	100%			1	0.06	1	2	100%		-	
Eravacycline	30.0	0.12	0.03	0.25		-		0.06	0.12	0.03	0.12	-			0.06		0.03	30.0				
Levofloxacin	>8	>8	> 8	> 8	0%	0%	100%	> 8	>8	> 8	> 8	0%	0%	100%	>8	>8	0.5	>8	30%	0%	71	
Linezolid	2	2	1	2	100%	0%	0%	2	2	2	2	100%	0%	0%	1	1	1	1	100%	0%	0	
Minocycline	>8	>8	0.06	> 8	26.3%	21.1%	52.6%	> 8	>8	4	> 8	16.7%	16.7%	66.7%	>8	>8	0.06	>8	20%	20%	61	
Penicillin	4	8	1	> 8	94.7%	-	5.3%	4	8	2	8	100%		0%	4	4	2	8	100%		С	
Tetracycline	> 32	> 32	0.25	> 32	15.8%	0%	84.2%	32	> 32	32	> 32	0%	0%	100%	> 32	> 32	0.5	> 32	10%	0%	91	
Tigecycline	0.12	0.5	0.06	0.5	-	-		0.12	0.25	0.12	0.25	-			0.12	0.25	0.12	0.25		-		
Vancomycin	> 32	> 32	> 16	> 32	0%	0%	100%	> 32	> 32	>16	> 32	0%	0%	100%	> 16	> 16	>16	>16	0%	0%	10	
	E. foec	ium (400)	1					£. face	cium (50)						E. fac	cium (237)						
Amoxicilin Clavulanate	>16	>16	≤ 0.12	> 16				> 16	>16	≤ 0.12	> 16				>1	>1	≤ 0.12	>1				
Azithromycin	>8	>8	0.25	> 8				>8	> 8	0.5	>8											
Ceftriaxone	>64	>64	1	> 64				> 64	> 64	2	> 64											
Daptomycin	4	4	0.12	>4	91.8%			4	>4	1	>4	72.9%			2	4	0.12	8	99.6%			
Levofloxacin	>8	>8	0.06	> 8	6%	6.5%	87.5%	>8	>8	1	>8	8.5%	8.5%	83.1%	>8	>8	0.12	>8	12.2%	1.3%	86	
Lineaplid	2	2	≤ 0.5	> 8	98.3%	1%	0.8%	2	2	1	8	94.9%	3.4%	1.7%	1	2	0.5	4	22.6%	0.4%	c	
Minocycline	8	>8	≤ 0.03	>8	47%	17.3%	35.8%	8	>8	≤ 0.03	>8	37.3%	15.3%	47.5%	0.25	>8	≤ 0.03	>8	60.3%	19%	20	
Penicillin	>8	>8	≤ 0.12	>8	9%		91%	>8	>8	≤ 0.12	>8	11.9%		88.1%	>8	>8	≤ 0.06	>8	11%		82	
Tetracycline	32	> 32	0.12	> 32	32.3%	0.3%	67.5%	32	> 32	0.12	> 32	30.5%	0%	69.5%	2	> 32	0.12	> 32	50.6%	0%	49	
Tirrecycline	0.12	0.25	0.03	4	96%			0.12	0.12	0.03	1	93.2%			0.06	0.12	0.03		98.7%			
Vancomycin	>16	> 32	≤ 0.12	> 32	43.2%	1%	55.8%	> 32	> 32	0.5	> 32	44.1%	1.7%	54.2%	1	> 16	≤ 0.25	>16	76.4%	0%	23	
	E foor	ium. VR (	222)					E from	rium. VR	1321					r form	cium. VR (56)						
Amoxicillin Clavulanate	>16	>16	≤0.12	> 16		_		> 16	>16	2	> 16	_	-	-	>1	>1	>1	>1		-		
Azithromycin	18	-8	0.25	- 8				18	18	4	18	_	_									
Ceftriaxone	>64	> 64	1	> 64				> 64	> 64	>64	> 64											
Daptomycin	4	4	0.12	>4	93.2%			4	>4	1	>4	78.1%			2	4	0.5		98.2%			
Enavarysine	0.06	0.06	0.008	- 74	72471	-	_	0.06	0.25	0.03	0.5	70.270	-	_	0.00	0.06	0.015	i.	20.2.0	-		
Levofloxacin	>8	>8	8	>8	0%	0%	100%	>8	>8	>8	>8	0%	0%	100%	>8	>8	> 8	>8	0%	0%	10	
Linezolid	2	2	s 0.5	>8	98.7%	0.5%	0.9%	2	2	1	8	96.9%	0%	3.1%	1	1	0.5	2	100%	0%		
Minocycline	8	18	0.06	- 8	41.9%	17.6%	40.5%	>8	>8	0.06	>8	21.9%	21.9%	56.3%		>8	0.06	>8				
Nanocycana Panirillin	**	>8	3.8	> 8	41.5%	17.0%	100%	> 8	>8	3.8	> 8	21.9%	21.9%	100%	-8	>8	2	>8	42.8%	35.7%	21	
			0.12								>8	12 5%		87 5%		>8	0.12		3.6%		96	
Tetracycline	32	> 32		> 32	18.9%	0.5%	80.6%	> 32	> 32	0.12		12.5%	0%	67.5%	32			> 32	28.6%	0%	71	
		0.25	0.03	4		-		0.12	0.5	0.06	1	-			0.12	0.12	0.03	1				
Tigecycline Vancomycin	> 32	> 32	> 16	> 32	0%	0%	100%	> 32	> 32	>32	> 32	0%	0%	100%	> 16	>16	>16	>16	0%	0%	10	

#### Conclusions

- ERV demonstrated consistent and potent in vitro activity against a global collection of Staphylococcus spp. and Enterococcus spp., including resistant strains, over a recent 3-year time period (2013-2015).
- ERV shows promising activity against globally-isolated Gram-positive organisms, including those with resistant phenotypes.

#### References

- Sievert D, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2005 2010. Infect Control Hose Indianois Joshania Charlot
- Centers for Disease Control; 2013: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed to the 26 2016.
- 3. Munita JM, et al.. Evolving Resistance Among Gram-positive Pathogens. Clin Infect Dis. 2015; 61(S2):S48-57
- CLSI, 2015. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standard-Eighth Edition M07-A10. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA 19087-1898
- CLSI, 2015. Performance Standards for Antimicrobial Susceptibility Testing; Informational Supplement-Twenty Second Edition M100-S25. Clinical and Laboratory Standards Institute (CLSI), Wayne, PA 19087-1898 USA.
- 6. http://www.accessdata.fda.gov/drugsatfda\_docs/label/2010/021821s021lbl.pdf